Wave Life Sciences is trading 7.90% up at $3.99 before the October 1, 2026 market open after GSK's September 30 selection of its Wave-developed candidate for a liver disease indication triggered a $12 million milestone payment. - Wave is eligible for additional milestones and royalties; three other collaboration programs are advancing toward possible selection. - After recent declines, including a 9.20% drop on September 23, no October 1 announcement was found; GSK news is a stronger explanation than modest broader-market gains.